Related Experiment Video
Updated: Mar 21, 2026
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
1Department of Pediatrics, Stanford University, Stanford, California; Department of Genetics, Stanford University, Stanford, California.
Abstract:
The activity of the RAF/MEK/ERK signaling pathway is critical for the proliferation of normal and cancerous cells. Oncogenic mutations driving the development of lung adenocarcinoma often activate this signaling pathway. In contrast, pathway activity levels and their biological roles are not well established in small cell lung cancer (SCLC), a fast-growing neuroendocrine lung cancer subtype. Here we discuss the function of the RAF/MEK/ERK kinase pathway and the mechanisms leading to its activation in SCLC cells. In particular, we argue that activation of this pathway may be beneficial to the survival, proliferation, and spread of SCLC cells in response to multiple stimuli. We also consider evidence that high levels of RAF/MEK/ERK pathway activity may be detrimental to SCLC tumors, including in part by interfering with their neuroendocrine fate. On the basis of these observations, we examined when small molecules targeting kinases in the RAF/MEK/ERK pathway may be useful therapeutically in patients with SCLC, including in combination with other therapeutic agents.
Insights
The RAF/MEK/ERK pathway impacts cell growth in lung cancers. This review explores its role in small cell lung cancer (SCLC) and potential therapeutic targeting.
Area of Science:
- Molecular Biology
- Oncology
- Cell Signaling
Background:
- The RAF/MEK/ERK signaling pathway is crucial for cell proliferation in normal and cancerous cells.
- While oncogenic mutations frequently activate this pathway in lung adenocarcinoma, its role in small cell lung cancer (SCLC) is less understood.
- SCLC is a distinct, aggressive subtype of neuroendocrine lung cancer.
Purpose of the Study:
- To elucidate the function and activation mechanisms of the RAF/MEK/ERK pathway in SCLC.
- To evaluate the dual role of pathway activation in SCLC survival, proliferation, and spread versus potential detrimental effects on neuroendocrine differentiation.
- To explore therapeutic strategies targeting RAF/MEK/ERK pathway kinases in SCLC patients.
Main Methods:
- Review of existing literature on RAF/MEK/ERK pathway signaling in lung cancer.
- Analysis of mechanisms driving pathway activation in SCLC.
- Examination of evidence for both beneficial and detrimental effects of pathway activity in SCLC.
- Consideration of therapeutic implications of targeting this pathway.
Main Results:
- The RAF/MEK/ERK pathway's activation may support SCLC cell survival, proliferation, and metastasis.
- High pathway activity could potentially hinder SCLC neuroendocrine differentiation, possibly impacting tumor behavior.
- The pathway presents a potential therapeutic target in SCLC.
Conclusions:
- The RAF/MEK/ERK pathway plays a complex role in SCLC, influencing key cellular processes.
- Targeting this pathway, potentially in combination therapies, may offer a therapeutic avenue for SCLC patients.
- Further research is warranted to fully understand and exploit the therapeutic potential of RAF/MEK/ERK pathway inhibitors in SCLC.
Related Concept Videos
01:07MAPK Signaling Cascades
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:23Abnormal Proliferation
02:23Master Transcription Regulators
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...